EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predicting Residual 21‐Hydroxylase Enzymatic Activity in Pediatric and Adult Congenital Adrenal Hyperplasia Patients: Towards Individualized Therapy

Davide Bindellini iD, Robin Michelet iD, Yersultan Mirasbekov, Qizong Lao iD, Charles Sukin, Wilhelm Huisinga iD, Deborah P Merke iD, Charlotte Kloft iD

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.70086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Davide Bindellini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Hydrocortisone, Steroid 21-Hydroxylase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Congenital adrenal hyperplasia (CAH) is a genetic disorder characterized by impaired cortisol production and consequent elevated adrenocorticotropic hormone (ACTH): CAH patients often require lifelong hydrocortisone therapy. Disease severity reflects residual 21‐hydroxylase enzyme activity, crucial for cortisol synthesis. Accurate assessment of residual enzymatic activity is key to developing individualized dosing. This study aimed to estimate enzymatic activity using a previously developed healthy adult ACTH‐cortisol model and to evaluate the potential for individualized therapy. Leveraging ACTH ( n = 62) and cortisol ( n = 66) concentrations from 51 (20 pediatric, 31 adult) untreated CAH patients, and assuming maximal cortisol production (E max ) = 100% in healthy individuals, residual enzymatic activity was estimated as an E max scaling factor. To assess proof‐of‐concept feasibility of individualized therapy, simulations of individual untreated 24‐h ACTH and cortisol profiles were performed, and for one patient hydrocortisone dosing regimens (15–25 mg/day in 3 doses, q4h or q6h) were compared to simulated untreated and healthy profiles. The original model failed to capture elevated ACTH in severe CAH and was refined to predict observed data across all patients. Using the refined model, estimated enzymatic activity was higher than in vitro values for adults, while children under 13 years old showed 31.6% of adult enzymatic activity. Shortening dosing intervals had a greater impact on reducing the patient's ACTH overexposure than increasing the daily dose. This model‐based approach captured in vivo endogenous cortisol production and enabled simulation‐based evaluation of individualized therapy in adults. In children, further validation of the ACTH‐cortisol dynamics model and enzymatic activity estimates is needed to evaluate individualized therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalHydrocortisoneSteroid 21-HydroxylaseHumansAdrenocorticotropic HormoneAdultPrecision MedicineChildFemaleAdolescentMaleYoung AdultChild, PreschoolModels, Biological

Stichwörter der Autor:innen

21‐hydroxylase deficiencyACTHcongenital adrenal hyperplasiacortisolhydrocortisonetherapy individualization

Substanzen

HydrocortisoneAdrenocorticotropic HormoneSteroid 21-Hydroxylase

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
  • Graduate Research Training Program PharMetrX, Berlin, Germany.
  • National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
  • Institute of Mathematics, University of Potsdam, Potsdam, Germany.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.

ORCID-Profile: Davide Bindellini, Robin Michelet, Qizong Lao, Wilhelm Huisinga, Deborah P Merke, Charlotte Kloft

Zitieren

APA

Bindellini, D., Michelet, R., Mirasbekov, Y., Lao, Q., Sukin, C., Huisinga, W., Merke, D. P., & Kloft, C. (2025). Predicting Residual 21‐Hydroxylase Enzymatic Activity in Pediatric and Adult Congenital Adrenal Hyperplasia Patients: Towards Individualized Therapy. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70086

Vancouver

Bindellini D, Michelet R, Mirasbekov Y, Lao Q, Sukin C, Huisinga W, et al. Predicting Residual 21‐Hydroxylase Enzymatic Activity in Pediatric and Adult Congenital Adrenal Hyperplasia Patients: Towards Individualized Therapy. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70086

BibTeX
@article{Bindellini2025,
  author = {Bindellini, Davide and Michelet, Robin and Mirasbekov, Yersultan and Lao, Qizong and Sukin, Charles and Huisinga, Wilhelm and Merke, Deborah P and Kloft, Charlotte},
  title = {Predicting Residual 21‐Hydroxylase Enzymatic Activity in Pediatric and Adult Congenital Adrenal Hyperplasia Patients: Towards Individualized Therapy},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.70086}
}
Kostenlos starten →